Mendel Haag, PhD, PharmD

CSL Seqirus, Netherlands

Disclosure(s): CSL Seqirus: Grant/Research Support, Stocks/Bonds (Private Company)

Poster(s):

• (P-1472) Comparable Vaccine Effectiveness of Adjuvanted and High-Dose Influenza Vaccines in Preventing Test-Confirmed Influenza Outcomes, including Hospitalization, in Overall and High-Risk Older Adults: A Test-Negative Design Study During 2022-2023 and 2023-2024
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1473) Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg-Based Influenza Vaccines During the 2023–2024 Season in the United States
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET